245 related articles for article (PubMed ID: 36551603)
1. New Insights into the Phenotype Switching of Melanoma.
Pagliuca C; Di Leo L; De Zio D
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551603
[TBL] [Abstract][Full Text] [Related]
2. Dynamical hallmarks of cancer: Phenotypic switching in melanoma and epithelial-mesenchymal plasticity.
Jain P; Pillai M; Duddu AS; Somarelli JA; Goyal Y; Jolly MK
Semin Cancer Biol; 2023 Nov; 96():48-63. PubMed ID: 37788736
[TBL] [Abstract][Full Text] [Related]
3. Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma.
Benboubker V; Boivin F; Dalle S; Caramel J
Front Immunol; 2022; 13():873116. PubMed ID: 35432344
[TBL] [Abstract][Full Text] [Related]
4. Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy.
Huang F; Santinon F; Flores González RE; Del Rincón SV
Front Oncol; 2021; 11():756001. PubMed ID: 34604096
[TBL] [Abstract][Full Text] [Related]
5. Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications.
Massi D; Mihic-Probst D; Schadendorf D; Dummer R; Mandalà M
Cancer Treat Rev; 2020 Aug; 88():102060. PubMed ID: 32619863
[TBL] [Abstract][Full Text] [Related]
6. Exploring the Complex and Multifaceted Interplay between Melanoma Cells and the Tumor Microenvironment.
Kuras M
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762707
[TBL] [Abstract][Full Text] [Related]
7. Cellular Reprogramming-A Model for Melanoma Cellular Plasticity.
Granados K; Poelchen J; Novak D; Utikal J
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167306
[TBL] [Abstract][Full Text] [Related]
8. How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance.
Wessely A; Steeb T; Berking C; Heppt MV
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071193
[TBL] [Abstract][Full Text] [Related]
9. Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma.
Najem A; Soumoy L; Sabbah M; Krayem M; Awada A; Journe F; Ghanem GE
Cells; 2022 Mar; 11(7):. PubMed ID: 35406721
[TBL] [Abstract][Full Text] [Related]
10. The mechanical phenotypic plasticity of melanoma cell: an emerging driver of therapy cross-resistance.
Diazzi S; Tartare-Deckert S; Deckert M
Oncogenesis; 2023 Feb; 12(1):7. PubMed ID: 36774337
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma.
Roesch A; Paschen A; Landsberg J; Helfrich I; Becker JC; Schadendorf D
Eur J Cancer; 2016 May; 59():109-112. PubMed ID: 27023049
[TBL] [Abstract][Full Text] [Related]
12. Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells.
Knappe N; Novak D; Weina K; Bernhardt M; Reith M; Larribere L; Hölzel M; Tüting T; Gebhardt C; Umansky V; Utikal J
Stem Cells; 2016 Apr; 34(4):832-46. PubMed ID: 26753613
[TBL] [Abstract][Full Text] [Related]
13. Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance.
Hammerlindl H; Schaider H
J Cell Commun Signal; 2018 Mar; 12(1):133-141. PubMed ID: 29192388
[TBL] [Abstract][Full Text] [Related]
14. Systems-level network modeling deciphers the master regulators of phenotypic plasticity and heterogeneity in melanoma.
Pillai M; Jolly MK
iScience; 2021 Oct; 24(10):103111. PubMed ID: 34622164
[TBL] [Abstract][Full Text] [Related]
15. Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies.
Diazzi S; Tartare-Deckert S; Deckert M
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32466585
[TBL] [Abstract][Full Text] [Related]
16. Transition Therapy: Tackling the Ecology of Tumor Phenotypic Plasticity.
Aguadé-Gorgorió G; Kauffman S; Solé R
Bull Math Biol; 2021 Dec; 84(1):24. PubMed ID: 34958403
[TBL] [Abstract][Full Text] [Related]
17. ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.
Richard G; Dalle S; Monet MA; Ligier M; Boespflug A; Pommier RM; de la Fouchardière A; Perier-Muzet M; Depaepe L; Barnault R; Tondeur G; Ansieau S; Thomas E; Bertolotto C; Ballotti R; Mourah S; Battistella M; Lebbé C; Thomas L; Puisieux A; Caramel J
EMBO Mol Med; 2016 Oct; 8(10):1143-1161. PubMed ID: 27596438
[TBL] [Abstract][Full Text] [Related]
18. Significance of RB Loss in Unlocking Phenotypic Plasticity in Advanced Cancers.
Venkadakrishnan VB; Yamada Y; Weng K; Idahor O; Beltran H
Mol Cancer Res; 2023 Jun; 21(6):497-510. PubMed ID: 37052520
[TBL] [Abstract][Full Text] [Related]
19. Melanoma Progression Inhibits Pluripotency and Differentiation of Melanoma-Derived iPSCs Produces Cells with Neural-like Mixed Dysplastic Phenotype.
Castro-Pérez E; Rodríguez CI; Mikheil D; Siddique S; McCarthy A; Newton MA; Setaluri V
Stem Cell Reports; 2019 Jul; 13(1):177-192. PubMed ID: 31231022
[TBL] [Abstract][Full Text] [Related]
20. Drugging the Epigenome: Overcoming Resistance to Targeted and Immunotherapies in Melanoma.
Hanly A; Gibson F; Nocco S; Rogers S; Wu M; Alani RM
JID Innov; 2022 Mar; 2(2):100090. PubMed ID: 35199090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
